
Tiakis Biotech appoints Christoph Schmidt to supervisory board
Ella Day | May 22, 2025 | Appointment | Research and Development | Cardiology, Tiakis Biotech, cardiovascular diseases, pulmonary arterial hypertension
Tiakis Biotech has announced the appointment of Christoph Schmidt to its supervisory board. Based in Kiel, Germany, the clinical-stage biotech company is developing therapies for life-threatening pulmonary and cardiovascular diseases, including pulmonary arterial hypertension (PAH).
Schmidt brings nearly 30 years of global experience in the life sciences industry, having held senior roles at Actelion and Johnson & Johnson. At both, he was involved in the successful global launch of four blockbuster therapies, including three treatments for PAH.
Alongside his commercial expertise, Schmidt has served as a non-executive director and investor across the biotechnology and medtech sectors. He is currently a senior advisor to Bain & Company among other consultancies and founded Executegy, a strategy firm focused on the life sciences industry.
Martin Voss, CEO of tiakis Biotech AG, said: “We are delighted to welcome Christoph Schmidt to the supervisory board. His deep experience and strategic insight will support Tiakis as we continue to develop Tiprelestat and advance our pipeline.”
Commenting on his appointment, Schmidt said: “I am pleased to join Tiakis and contribute to the development of Tiprelestat, which I believe has strong disease-modifying potential in PAH. I look forward to working with the team to support patients affected by this serious condition.”
Ella Day
22/5/25
Related Content

FDA approves Merck’s Winrevair for PAH treatment
Merck, known as MSD outside of the US and Canada, has announced that the US …

FDA approves J&J’s Opsynvi for PAH treatment
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has …

United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure
United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) …






